Knee implant maker Moximed announced today that it closed a Series D preferred stock financing worth up to $91 million. The funding round includes $61 million and an option to close on up to an additional $30 million. ELevage Medical Technologies, a Patient Square Capital platform, led the round. New investors Cormorant Asset Management and […]
Moximed
Moximed names Christopher Gleason as CEO
Moximed today announced it appointed Christopher Gleason as president and CEO, effective immediately. Most recently, Gleason was VP of sales at Relievant, which was acquired by Boston Scientific for $850 million in September last year. He has also served as VP of sales of interventional urology at Teleflex and in other sales leadership roles at […]
Moximed implants first Misha knee shock absorber
Moximed announced today that doctors completed the first commercial cases for its Misha knee system, an implantable shock absorber (ISA). In April, the FDA granted Misha de novo clearance for the treatment of medial knee osteoarthritis (OA). Its indication covers people with medial knee OA who failed to find relief from non-surgical or surgical treatment. […]
Moximed wins FDA nod for implantable shock absorber for knee osteoarthritis
Moximed announced that the FDA granted de novo marketing authorization for its Misha knee system for treating knee osteoarthritis (OA). Misha, an implantable shock absorber, treats people with medial knee OA. These patients failed to find relief from non-surgical or surgical treatment. This population continues to experience pain that interferes with daily activities. Due to […]
Moximed raises $40M for implantable shock absorber for knee osteoarthritis
Knee osteoarthritis (OA) treatment developer Moximed announced today that it raised $40 million in a Series C equity and debt financing. Fremont, California–based Moximed will use the proceeds from the financing to pursue regulatory approvals and establish commercial infrastructure for its Misha knee system — the world’s first implantable shock absorber (ISA) for the knee. […]
Moximed’s ‘shock absorber for the knee’ trial begins
Moximed said that surgeons have implanted its Calpyso knee unloading system in the first osteoarthritis patient in its U.S. clinical trial. The Calypso is designed to work like a shock absorber for the knee by restoring a more normal load balance within the joint. It may help prevent or delay total knee replacement, according to […]
These medtech companies raised the most VC last year
Perhaps there’s a ray of hope that venture capital funding is recovering a bit for the medical device industry. VC firms invested more than $2.8 billion in 2017, an increase of more than $647 million from 2016, according to the MoneyTree Report from PricewaterhouseCoopers (PwC) and CB Insights. There were a total 229 deals involving […]
Moximed closes $50m Series C
California orthopedic device developer Moximed said today it raised $50 million in a Series C round of financing. The round was joined by newly invested Advent Life Sciences and Future fund and existing investors NEA, Morgenthaler Ventures, Gilde Healthcare, GBS Venture Partners and Vertex Healthcare. “This financing round is timely, as we are completing the primary […]
Moximed launches IDE trial of Atlas unicompartmental knee
California orthopedic device developer Moximed said today it enrolled the 1st patient in an FDA approved investigational device exemption trial of its next-gen Atlas unicompartmental unloading knee implant. The Atlas is designed to treat osteoarthritis knee joint pain in patients ages 35 to 65 whose condition has not degenerated enough to require arthroplasty. The device is a joint unloader […]
CE Mark in hand, Moximed hatches U.S. approval strategy for knee stabilization implant
The knee replacement market has reached stratospheric levels in the U.S., with competitors ranging from Zimmer Biomet (NYSE:ZBH) to Smith & Nephew (NYSE:SNN) and Johnson & Johnson (NYSE:JNJ). California device developer Moximed is betting its future, however, on patients not quite ready for the drastic surgery. The knee replacement market is worth an estimated $4 billion […]
Moximed wins CE Mark for Atlas ‘shock absorbing’ knee
Moximed said last week it won CE Mark approval in the European Union for its Atlas ‘shock absorber’ knee joint unloader for pre-arthroplasty patients. The Atlas system is an implantable joint unloader placed subcutaneously along the knee joint to absorb excess joint load rather than transfer it to healthy areas of the joint, the Hayward, […]
